- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
42 result(s) found for: Venipuncture.
Displaying page 1 of 3.
EudraCT Number: 2014-001751-23 | Sponsor Protocol Number: 6/13 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:IRCCS Burlo Garofolo | |||||||||||||
Full Title: Comparative evaluation of the effectiveness of EMLA vs. Ralydan in the procedures for venipuncture and venous cannulation. Randomized controlled trial.. | |||||||||||||
Medical condition: Procedures for venipuncture and venous incannulation in pediatric patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000750-37 | Sponsor Protocol Number: 35711 | Start Date*: 2011-03-29 |
Sponsor Name:Isala Klinieken | ||
Full Title: A randomised clinical trial on the effectiveness of Emla and Rapydan for prevention of vena punction-induced pain in children. | ||
Medical condition: Venipuncture, especially in children, is associated with pain and discomfort. For this reason, often use a local anesthetic. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005334-22 | Sponsor Protocol Number: 347PUNCIOHEMODIALISIS | Start Date*: 2016-05-31 |
Sponsor Name:HOSPITAL DE PALAMÓS | ||
Full Title: CLINICAL TRIAL FOR THE TREATMENT OF PAIN IN HEMODIALYSIS PUNCTURE WITH LIDOCAINE / PRILOCAINE, VERSUS CHLOROETHYL, CROSSOVER RANDOMIZED STUDY | ||
Medical condition: Hemodialysis is the most commonly used therapy for renal replacement being the arteriovenous fistula used for vascular access . Venipuncture in patients causes stress, pain and anxiety. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002403-29 | Sponsor Protocol Number: DAM001DFM | Start Date*: 2017-04-25 |
Sponsor Name:Di-AcetylM B.V. | ||
Full Title: Pharmacokinetics of new dexamphetamine sustained release tablets and the clinical validation of measuring dexamphetamine in dried blood spots | ||
Medical condition: No condition is investigated. The primary aim is to investigate the pharmacokinetics of the new formulation | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003991-27 | Sponsor Protocol Number: D1690C00047 | Start Date*: 2017-12-27 |
Sponsor Name:AstraZeneca AB | ||
Full Title: MAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Sk... | ||
Medical condition: Study to investigate mitochondrial function and insulin sensitivity in skeletal muscle in subjects with T2DM. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-013107-56 | Sponsor Protocol Number: 460/09 | Start Date*: 2009-09-21 | ||||||||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | ||||||||||||||||||
Full Title: Phase II trial with intranasal Midazolam delivered using a MAD (Mucosal Atomizer Device) for paediatric painful procedures. | ||||||||||||||||||
Medical condition: painful procedures in paediatric oncology | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005127-27 | Sponsor Protocol Number: CIGE025ENL01T | Start Date*: 2015-05-29 |
Sponsor Name:UMC Utrecht | ||
Full Title: Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria | ||
Medical condition: Chronic spontaneous urticaria | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003647-28 | Sponsor Protocol Number: NA | Start Date*: 2020-12-09 |
Sponsor Name: | ||
Full Title: Differences in antihypertensive drug levels in patients with hypertension: old vs young 2 | ||
Medical condition: Hypertension Cardiovascular disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003176-13 | Sponsor Protocol Number: 67133 | Start Date*: 2019-02-18 |
Sponsor Name:Maastricht University | ||
Full Title: Lowering Branched-Chain Amino Acids as a New Strategy to Treat Diabetes | ||
Medical condition: type 2 diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-005006-31 | Sponsor Protocol Number: EML053774_002 | Start Date*: 2007-04-03 |
Sponsor Name:Merck Sante France | ||
Full Title: A randomized, stratified on age, parallel group design study to investigate the safety, tolerability and pharmacokinetics after a 60 minutes application of 4% lidocaine cream compared to EMLA® crea... | ||
Medical condition: Topical anesthesia of healthy skin before venous or subcutaneous puncture, before superficial cutaneous instrumental surgery or laser beam (tattoo or cutaneousangioma) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001301-24 | Sponsor Protocol Number: IIV-407 | Start Date*: 2020-03-20 |
Sponsor Name:National Institute for Public Health and the Environment (RIVM) | ||
Full Title: ‘Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in t... | ||
Medical condition: The tetravelent MenACWY-TT vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup A, C, W and Y. | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000717-20 | Sponsor Protocol Number: SP0967 | Start Date*: 2015-06-03 | |||||||||||
Sponsor Name:UCB Biosciences Inc. | |||||||||||||
Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY ≥1 MONTH TO <4... | |||||||||||||
Medical condition: Epilepsy with partial onset seizures | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) CZ (Completed) LT (Completed) IT (Completed) DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) PL (Completed) RO (Completed) GR (Completed) BG (Completed) HR (Completed) SK (Completed) BE (Completed) PT (Completed) DK (Prematurely Ended) FI (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000788-98 | Sponsor Protocol Number: D5320C00001 | Start Date*: 2013-06-18 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females with Polycystic Ovary ... | |||||||||||||
Medical condition: Polycystic Ovary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002629-36 | Sponsor Protocol Number: SP1047 | Start Date*: 2014-08-06 |
Sponsor Name:UCB Biosciences, Inc | ||
Full Title: A multicenter, open-label study to investigate the pharmacokinetics of commercial lacosamide oral formulation as therapy in children (aged 1 month to 17 years) with epilepsy. | ||
Medical condition: Epilepsy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-001060-36 | Sponsor Protocol Number: MTE08 | Start Date*: 2008-09-05 | |||||||||||
Sponsor Name:Acrux Pharma Pty Ltd | |||||||||||||
Full Title: A Phase III open-label titration trial to evaluate the effectiveness and safety of different doses of a dermal application of Testosterone MD-Lotion® (cutaneous solution) in hypogonadal men | |||||||||||||
Medical condition: Male Hypogonadism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005145-12 | Sponsor Protocol Number: HIDRA03 | Start Date*: 2012-02-08 | |||||||||||
Sponsor Name:University of Athens, Medical School | |||||||||||||
Full Title: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF ANAKINRA IN PATIENTS WITH HIDRADENITIS SUPPURATIVA (PROTOCOL: HIDRA03) | |||||||||||||
Medical condition: Hidradenitis suppurativa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005788-34 | Sponsor Protocol Number: NL79578.100.21 | Start Date*: 2022-03-31 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect | ||
Medical condition: Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-005030-38 | Sponsor Protocol Number: PAT-CR-302 | Start Date*: 2019-08-10 | |||||||||||
Sponsor Name:Vifor Pharma, Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone Syst... | |||||||||||||
Medical condition: Management of hyperkalemia due to renin-angiotension-aldosterone system medications in patients treated for heart failure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Completed) NL (Completed) ES (Ongoing) HU (Completed) DE (Completed) BG (Completed) GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007672-41 | Sponsor Protocol Number: Protocol B4Z-MC-LYDO | Start Date*: 2008-12-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Cont... | |||||||||||||
Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SE (Completed) AT (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004934-32 | Sponsor Protocol Number: IRUSZACT0098 | Start Date*: 2012-03-07 | |||||||||||
Sponsor Name:National Cancer Institute | |||||||||||||
Full Title: A phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid cancer. | |||||||||||||
Medical condition: Hereditary medullary thyroid cancer | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
